297 related articles for article (PubMed ID: 18405181)
1. Long-term bexarotene monotherapy in large cell CD30+ pleomorphic T-cell lymphoma.
Aldaoud A
Dermatol Clin; 2008 Jan; 26 Suppl 1():15-7. PubMed ID: 18405181
[No Abstract] [Full Text] [Related]
2. Bexarotene monotherapy for epidermotropic CD8+ CTCL.
Kamstrup M; Gniadecki R
Dermatol Clin; 2008 Jan; 26 Suppl 1():45-7. PubMed ID: 18405187
[No Abstract] [Full Text] [Related]
3. Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy.
French LE; Shapiro M; Junkins-Hopkins JM; Vittorio CC; Rook AH
J Am Acad Dermatol; 2001 Dec; 45(6):914-8. PubMed ID: 11712039
[TBL] [Abstract][Full Text] [Related]
4. Extracutaneous tumour mass following bexarotene and interferon therapy of primary cutaneous CD30+ large cell lymphoma.
Kreuter A; Altmeyer P; Gambichler T
Acta Derm Venereol; 2006; 86(3):274-5. PubMed ID: 16710601
[No Abstract] [Full Text] [Related]
5. Primary cutaneous CD30 positive anaplastic large cell lymphoma--report of a case treated with bexarotene.
Oliveira A; Fernandes I; Alves R; Lima M; Selores M
Leuk Res; 2011 Nov; 35(11):e190-2. PubMed ID: 21764128
[No Abstract] [Full Text] [Related]
6. Topical and oral bexarotene.
Schadt CR
Dermatol Ther; 2013; 26(5):400-3. PubMed ID: 24099070
[TBL] [Abstract][Full Text] [Related]
7. Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma.
Ballanger F; Nguyen JM; Khammari A; Dréno B
Dermatology; 2010; 220(4):370-5. PubMed ID: 20484880
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
9. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.
Väkevä L; Ranki A; Hahtola S
Acta Derm Venereol; 2012 May; 92(3):258-63. PubMed ID: 22678563
[TBL] [Abstract][Full Text] [Related]
10. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
[TBL] [Abstract][Full Text] [Related]
11. Combination treatment modalities in cutaneous T-cell lymphoma (CTCL).
Guitart J
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S17-20. PubMed ID: 16516671
[TBL] [Abstract][Full Text] [Related]
12. About the cutaneous targets of bexarotene in CTCL patients.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e299-301. PubMed ID: 19845753
[TBL] [Abstract][Full Text] [Related]
13. Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas.
Martin AG
J Drugs Dermatol; 2003 Apr; 2(2):155-67. PubMed ID: 12852367
[TBL] [Abstract][Full Text] [Related]
14. Folliculotropic mycosis fungoides with CD30+ large-cell transformation in a young woman: beneficial effect of bexarotene.
Mitteldorf C; Stadler R; Bertsch HP; Neumann C
Br J Dermatol; 2007 Mar; 156(3):584-6. PubMed ID: 17300259
[No Abstract] [Full Text] [Related]
15. Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma.
Shapiro M; Rook AH; Lehrer MS; Junkins-Hopkins JM; French LE; Vittorio CC
J Am Acad Dermatol; 2002 Dec; 47(6):956-61. PubMed ID: 12451388
[No Abstract] [Full Text] [Related]
16. Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
Whitmore SE
J Am Acad Dermatol; 2004 Sep; 51(3):482; author reply 482-3. PubMed ID: 15338005
[No Abstract] [Full Text] [Related]
17. Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids.
Musolino A; Panebianco M; Zendri E; Santini M; Di Nuzzo S; Ardizzoni A
Br J Haematol; 2009 Apr; 145(1):84-6. PubMed ID: 19208096
[TBL] [Abstract][Full Text] [Related]
18. Molecular markers associated with clinical response to bexarotene therapy in cutaneous T-cell lymphoma.
Ranki A; Väkevä L; Sipilä L; Krohn K
Acta Derm Venereol; 2011 Sep; 91(5):568-73. PubMed ID: 21547336
[TBL] [Abstract][Full Text] [Related]
19. Bexarotene monotherapy for patients with refractory Sézary syndrome.
Staib G; Scharffetter-Kochanek K
Dermatol Clin; 2008 Jan; 26 Suppl 1():61-3. PubMed ID: 18405190
[No Abstract] [Full Text] [Related]
20. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
Assaf C; Bagot M; Dummer R; Duvic M; Gniadecki R; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2006 Aug; 155(2):261-6. PubMed ID: 16882161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]